NovaBay Pharmaceuticals Signs Definitive Agreement to Sell its Avenova Assets
NovaBay Pharmaceuticals, Inc. (NBY)
NASDAQ:AMEX Investor Relations:
novabay.com/investors
Company Research
Source: Business Wire
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces it has entered into a definitive asset purchase agreement (the “Agreement”) with PRN Physician Recommended Nutriceuticals, LLC (“PRN”) to sell the assets of its Avenova® brand and business for $9.5 million in cash. The transaction has been approved by the Company’s board of directors and is anticipated to close in the fourth quarter of 2024, subject to the satisfaction of customary closing conditions, including approval from the stockholders of NovaBay.“This transaction allows our stockholders to more fully realize the value we have created over the past 10 years with the Avenova brand. We are particularly pleased to place Avenova with PRN, a well-established eyecare company that shares our commitment to providing best-in-class products that support ocular health,” said Justin Hall, NovaBay CEO. “I believe we have found an ideal home for Avenova. We expec
Show less
Read more
Impact Snapshot
Event Time:
NBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBY alerts
High impacting NovaBay Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
NBY
News
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BTTR, NBY, ARC on Behalf of ShareholdersPR Newswire
- Kuehn Law Encourages COFS, ARC, RFL, and NBY Investors to Contact Law FirmPR Newswire
- NovaBay Pharmaceuticals, Inc. (NYSE: NBY) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- NBY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NovaBay Pharmaceuticals, Inc.’s Avenova Brand and Business Is Fair to ShareholdersBusiness Wire
- Acumen Health Holdings ("Acumen") to Acquire the Avenova brand from NovaBay PharmaceuticalsPR Newswire
NBY
Sec Filings
- 9/25/24 - Form PREM14A
- 9/20/24 - Form DEFA14A
- 9/20/24 - Form 8-K
- NBY's page on the SEC website